While there is ongoing research to develop better tools like biochemical markers to differentiate fibrosis stage in MASH patients, the only standard currently used in MASH clinical studies involves ...

There are now more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

SIGA Technologies has gained the Japanese regulatory approval for TEPOXX (tecovirimat) for the treatment of smallpox, mpox and cowpox.

China NMPA has granted acceptance and priority review for the NDA for HUTCHMED’s ORPATHYS (savolitinib) and TAGRISSO (osimertinib) combination ...